We are live on ! Find out more
GILD icon

Gilead Sciences

1,575 hedge funds and large institutions have $73.2B invested in Gilead Sciences in 2017 Q4 according to their latest regulatory filings, with 202 funds opening new positions, 535 increasing their positions, 691 reducing their positions, and 116 closing their positions.

New
Increased
Maintained
Reduced
Closed

74% more first-time investments, than exits

New positions opened: 202 | Existing positions closed: 116

5% more funds holding

Funds holding: 1,5041,575 (+71)

1.25% more ownership

Funds ownership: 76.99%78.25% (+1.3%)

10% less capital invested

Capital invested by funds: $81.5B → $73.2B (-$8.37B)

23% less repeat investments, than reductions

Existing positions increased: 535 | Existing positions reduced: 691

40% less call options, than puts

Call options by funds: $1.57B | Put options by funds: $2.63B

46% less funds holding in top 10

Funds holding in top 10: 9652 (-44)

Holders
1,575
Holders Change
+71
Holders Change %
+4.72%
% of All Funds
35.71%
Holding in Top 10
52
Holding in Top 10 Change
-44
Holding in Top 10 Change %
-45.83%
% of All Funds
1.18%
New
202
Increased
535
Reduced
691
Closed
116
Calls
$1.57B
Puts
$2.63B
Net Calls
-$1.06B
Net Calls Change
-$328M
Name Holding Trade Value Shares
Change
Change in
Stake
PCG
1576
Private Capital Group
Connecticut
$323 +$342K +4,506 New
CCT
1577
Capital City Trust
Florida
$296 -$10.1K -133 -3%
NFA
1578
Nationwide Fund Advisors
Ohio
-$83.7M -1,032,650 Closed
FCM
1579
Farallon Capital Management
California
-$76.6M -945,000 Closed
GTP
1580
Global Thematic Partners
New York
-$58.1M -716,797 Closed
KSCM
1581
Key Square Capital Management
Connecticut
-$50.1M -617,992 Closed
WCM
1582
Wedge Capital Management
North Carolina
-$43.4M -535,474 Closed
CCM
1583
Camber Capital Management
Massachusetts
-$40.5M -500,000 Closed
MWNA
1584
Marshall Wace North America
New York
-$28.5M -352,434 Closed
MVP
1585
Miller Value Partners
Florida
-$26.2M -322,955 Closed
SAM
1586
Sectoral Asset Management
Quebec, Canada
-$19M -234,900 Closed
SFM
1587
Sphera Funds Management
Israel
-$18.6M -230,000 Closed
IAM
1588
Impax Asset Management
New Hampshire
-$14.7M -181,151 Closed
Cohen & Steers
1589
Cohen & Steers
New York
-$12M -148,696 Closed
BIM
1590
Bogle Investment Management
Massachusetts
-$10.6M -131,376 Closed
Jacobs Levy Equity Management
1591
Jacobs Levy Equity Management
New Jersey
-$9.96M -122,998 Closed
SGAM
1592
Smith Group Asset Management
Texas
-$8.96M -110,620 Closed
GCM
1593
Grisanti Capital Management
New York
-$8.71M -107,524 Closed
UONDDL
1594
University of Notre Dame du Lac
Indiana
-$8.12M -100,229 Closed
OA
1595
Opes Advisors
California
-$7.92M -97,789 Closed
LSA
1596
L & S Advisors
California
-$7.17M -88,531 Closed
NLI
1597
Nippon Life Insurance
Japan
-$6.65M -82,129 Closed
SGH
1598
Sivik Global Healthcare
Connecticut
-$6.48M -80,000 Closed
Lord, Abbett & Co
1599
Lord, Abbett & Co
New Jersey
-$5.06M -62,400 Closed
FIM
1600
Frontier Investment Management
Texas
-$4.97M -61,307 Closed

GILD Hedge Fund Activity: Q4 2017 in Review

1,575 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q4 2017, worth a combined $73.2B — down 10% from $81.5B a quarter earlier.

Buyers outnumbered sellers: 202 funds opened new GILD positions and 116 closed out — a net gain of 86 holders — while 535 added to existing stakes and 691 trimmed.

The largest buyer was Capital Research Global Investors, adding an estimated $794M. The largest seller was C WorldWide Group, cutting an estimated $300M.

  • 1,575 institutional investors held Gilead Sciences (GILD) as of Q4 2017, up from 1,504 in Q3 2017.
  • Funds reported $73.2B of Gilead Sciences stock for Q4 2017, down 10% quarter-over-quarter.
  • 202 funds opened new Gilead Sciences positions in Q4 2017 and 116 closed out, a net change of +86 holders.
  • The largest Gilead Sciences buyer in Q4 2017 was Capital Research Global Investors, an estimated $794M added.
  • The largest Gilead Sciences seller in Q4 2017 was C WorldWide Group, an estimated $300M sold.

Based on aggregated 13F filings for Q4 2017.